Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd.'s injectable Ruikang Luzetolatamab (injectable SHR-A2009) was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the China Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.